Lv5
1590 积分 2024-11-28 加入
Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission
13天前
已完结
[The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors]
1个月前
已关闭
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
2个月前
已完结
Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine
2个月前
已完结
ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany
3个月前
已完结
[Adalimumab (Humira)--efficacy in rheumatoid arthritis treatment with particular reference to working ability]
3个月前
已关闭
Adalimumab: a review of its use in adult patients with rheumatoid arthritis
3个月前
已完结
Changes in Concentrations of Free Propofol by Modification of the Solution
4个月前
已完结
The pharmacodynamic effects of a lower-lipid emulsion of propofol: a comparison with the standard propofol emulsion
4个月前
已完结
[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The best practice for TNF inhibitors.]
5个月前
已关闭
皖公网安备34019202002308
